您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Imatinib Impurity E
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Imatinib Impurity E
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Imatinib Impurity E图片
CAS NO:1365802-18-1
包装与价格:
包装价格(元)
1mg电议
5mg电议

产品介绍
ImatinibImpurityE是Imatinib的杂质。Imatinib是一种口服生物可用的酪氨酸激酶抑制剂,可选择性抑制BCR/ABL,v-Abl,PDGFR,c-kit激酶活性。Imatinib(STI571)靠近ATP结合位点结合,将其锁定在封闭或自我抑制的构象中,因此半竞争性抑制蛋白质的酶活性。Imatinib还抑制SARS-CoV和MERS-CoV。
Cas No.1365802-18-1
别名1,4-双-[4-[4-甲基-3-[[4-(吡啶-3-基)pyriMidin-2-yl]a氨基]苯基]氨基甲酰基]苄基哌嗪
Canonical SMILESO=C(NC1=CC=C(C)C(NC2=NC=CC(C3=CC=CN=C3)=N2)=C1)C4=CC=C(CN5CCN(CC6=CC=C(C=C6)C(NC7=CC=C(C)C(NC8=NC=CC(C9=CC=CN=C9)=N8)=C7)=O)CC5)C=C4
分子式C52H48N12O2
分子量873.02
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Imatinib Impurity E is the impurity of Imatinib. Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively[1][2][3][4]. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV[5].

[1]. Heinrich MC, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000 Aug 1;96(3):925-32. [2]. Guida T, et al. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res. 2007 Jun 1;13(11):3363-9. [3]. Iqbal N, et al. Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014:357027. [4]. Okuda K, et al. ARG tyrosine kinase activity is inhibited by STI571.Blood. 2001 Apr 15;97(8):2440-8. [5]. Jeanne M Sisk, et al. Coronavirus S Protein-Induced Fusion Is Blocked Prior to Hemifusion by Abl Kinase Inhibitors. J Gen Virol. 2018 May;99(5):619-630.